This transaction
Acquisition of IntraBioIt is stated that the company has new expertise and capabilities in rare diseases and develops and provides AQNEURSA®, a treatment for neurological symptoms of Niemann-Pick disease type C (NPC) and ataxia associated with ataxia-telangiectasia (A-T), but the business activities of the target company itself are Not disclosed
The impact on consolidated results for the fiscal year ending March 2027 is incorporated into the revised consolidated earnings forecasts announced on 29 October 2026
| Item | Details |
|---|---|
| Transaction name | Acquisition of IntraBio |
| Counterparty name | IntraBio Inc. |
| Name of the Subject Company | IntraBio Inc. |
| Business Description of the Subject Company | It is stated that the company has new expertise and capabilities in rare diseases and develops and provides AQNEURSA®, a treatment for neurological symptoms of Niemann-Pick disease type C (NPC) and ataxia associated with ataxia-telangiectasia (A-T), but the business activities of the target company itself are Not disclosed |
| Location of the Subject Company | Texas, USA |
| Impact on Business Performance | The impact on consolidated results for the fiscal year ending March 2027 is incorporated into the revised consolidated earnings forecasts announced on 29 October 2026 |
| Execution Date / Effective Date | 18 November 2026 (acquisition completed) |
| Management structure after acquisition | The programs initiated by IntraBio will be continued, and the potential of AQNEURSA in other rare diseases will be considered going forward. The trade name, representative and employee arrangements are Not disclosed |
Items this document does not state (24)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To expand and strengthen its global efforts in rare diseases by adding AQNEURSA to its portfolio and acquiring expertise and capabilities in rare diseases.